Alumis

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alumis sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Alumis: 13 sponsored US clinical trials, 1 recruiting.

Alumis sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plaque Psoriasis, with 4 trials.

Top-decile sponsor footprint

Alumis ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634
ACTIVE NOT RECRUITING Phase 3

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541
ACTIVE NOT RECRUITING Phase 3

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

NCT06586112
ACTIVE NOT RECRUITING Phase 2

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
ACTIVE NOT RECRUITING Phase 2

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

NCT05739435
COMPLETED Phase 1

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

NCT06962774
COMPLETED Phase 1

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

NCT07378579
COMPLETED Phase 1

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

NCT07442149
TERMINATED Phase 2

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

NCT05953688
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

NCT05600036
COMPLETED Phase 1

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

NCT05431634
COMPLETED Phase 1

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 4
Phase 3 3

Therapeutic Areas

Plaque Psoriasis 4
Severe Psoriasis 1
Moderate Psoriasis 1
Psoriasis (PsO) 1
SLE 1
Hepatic Impairment 1
Pharmacokinetics 1
Psoriasis 1

What is open in the Alumis pipeline

1 recruiting of 13 indexed (8% open); 6 completed (46%).

Phase mix: 3 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Plaque Psoriasis (4 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alumis: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Alumis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share AlumisAdaptimmuneAgennixAkili Interactive LabsAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterFresenius Medical Care North AmericaLG Chem
Alumis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alumis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alumis page

13 registered trials is a research-attention snapshot, not an endorsement of Alumis or any single study.

  • 1 of Alumis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Plaque Psoriasis is the condition Alumis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Plaque Psoriasis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alumis pipeline card: 13 registered trials from official public datasets.Report a data error.